What is Sofosbuvir + Ledipasvir?

Sofosbuvir + Ledipasvir is a highly effective, direct-acting antiviral (DAA) fixed-dose combination therapy used for the treatment of chronic Hepatitis C virus (HCV) infection. This single-tablet regimen combines two potent antiviral agents that directly target and disrupt different stages of the Hepatitis C viral replication cycle.

By combining a nucleotide analog polymerase inhibitor with an NS5A inhibitor, this treatment achieves exceptionally high cure rates—defined as Sustained Virologic Response (SVR12)—with a convenient, once-daily oral administration without the need for interferon injections.

What is Sofosbuvir + Ledipasvir Used For?

This combination regimen is prescribed for adult and pediatric patients (typically 3 years of age and older meeting specific weight criteria) for the treatment of chronic Hepatitis C virus (HCV) infection:

• Targeted Genotypes: Primarily indicated for HCV Genotypes 1, 4, 5, and 6.
• Liver Disease Spectrum: Approved for patients without cirrhosis (non-cirrhotic), patients with compensated cirrhosis, and (in combination with Ribavirin) patients with decompensated cirrhosis.
• Special Populations: Commonly prescribed for patients co-infected with HIV-1, post-liver transplant recipients, and treatment-experienced patients who failed prior therapies.

How Does Sofosbuvir + Ledipasvir Work?

The two active pharmaceutical ingredients act synergistically at distinct viral protein sites within the HCV replication complex:

• Sofosbuvir (NS5B Polymerase Inhibitor): Sofosbuvir is a nucleotide prodrug that converts intracellularly into its active triphosphate form. It incorporates into viral RNA via the HCV NS5B RNA-dependent RNA polymerase, causing immediate RNA chain termination and halting viral replication.
• Ledipasvir (NS5A Inhibitor): Ledipasvir selectively targets the HCV NS5A non-structural protein, a key phosphoprotein required for viral RNA replication, virion assembly, and secretion.
• Dual Molecular Suppression: Simultaneously blocking NS5B and NS5A prevents viral escape, rapidly suppresses HCV RNA viral loads to undetectable levels, and eliminates the virus from host liver cells.

Benefits of Sofosbuvir + Ledipasvir

• High Cure Rates (SVR12): Consistently achieves cure rates of 94% to 99% in Genotype 1 and 4 HCV infections across diverse patient populations.
• Interferon-Free Regimen: Completely eliminates the severe systemic toxicity and injections associated with historical pegylated interferon schedules.
• Convenient Single-Tablet Regimen (STR): Formulated as a single fixed-dose combination tablet taken once daily, ensuring high compliance and ease of administration.

Available Strengths

Sofosbuvir + Ledipasvir is manufactured as oral film-coated tablets in precise fixed-dose combination strengths for adult and pediatric use:

• Adult Strength:
o Sofosbuvir 400 mg / Ledipasvir 90 mg film-coated tablets
• Pediatric Strengths:
o Sofosbuvir 200 mg / Ledipasvir 45 mg film-coated tablets or oral pellets
o Sofosbuvir 150 mg / Ledipasvir 33.75 mg oral pellets

Recommended Dosage & Administration

Dosing duration depends on HCV genotype, treatment history, and whether cirrhosis is present.

Standard Adult Dosage Guidelines

• Standard Adult Regimen: One Sofosbuvir 400 mg / Ledipasvir 90 mg tablet taken orally once daily.
• Standard Treatment Duration:
o Treatment-naïve non-cirrhotic Genotype 1 (baseline HCV RNA < 6 million IU/mL): 8 weeks can be considered.
o Standard Treatment-naïve or Treatment-experienced with/without Compensated Cirrhosis: 12 weeks.
o Decompensated Cirrhosis or Post-Transplant: 12 to 24 weeks (co-administered with Ribavirin).

Administration Rules

• With or Without Food: Can be taken with or without food.
• Swallow Whole: Swallow tablets whole with water. Do not chew, split, or crush the tablets.
• Consistency is Key: Take your daily dose at approximately the same time every day to maintain steady antiviral concentrations in the blood.

Missed Dose

• If a dose is missed on a given day, take it as soon as remembered on that same day. If it is close to your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once. Common & Serious Side Effects

Sofosbuvir + Ledipasvir is generally well-tolerated with a favorable safety profile:

• Common Mild Effects: Fatigue/unusual tiredness, headache, nausea, insomnia, and mild dizziness.
• Hepatitis B Reactivation (Boxed Warning): Risk of severe acute flare-up or reactivation of Hepatitis B virus (HBV) in patients co-infected with HBV and HCV. All patients must be screened for HBV prior to initiating therapy.
• Severe Symptomatic Bradycardia: Co-administration with amiodarone (an antiarrhythmic drug) can cause life-threatening slowing of the heart rate (bradycardia), requiring alternative medication choices or strict cardiac monitoring.
• Anemia (when combined with Ribavirin): Significant decrease in red blood cell count requiring routine hemoglobin monitoring when Ribavirin is included in the treatment schedule.

Drug Interactions

Ledipasvir absorption is highly dependent on gastric pH, and both active ingredients are transported by P-glycoprotein (P-gp) and BCRP:

• Antacids & Gastric Acid Reducers: Acid-reducing medications significantly reduce Ledipasvir solubility and absorption:
o Antacids: Take antacids 4 hours before or 4 hours after this medication.
o H2 Blockers (e.g., famotidine): Take simultaneously or 12 hours apart at doses not exceeding famotidine 40 mg equivalent twice daily.
o Proton Pump Inhibitors (PPIs, e.g., omeprazole): PPI doses comparable to omeprazole 20 mg can be taken simultaneously with Sofosbuvir + Ledipasvir on an empty stomach.
• P-gp Inducers: Drugs like rifampin, carbamazepine, St. John’s Wort, oxcarbazepine, and phenytoin lower blood levels of Sofosbuvir and Ledipasvir, leading to loss of therapeutic response and potential treatment failure. Co-administration is contraindicated.
• Amiodarone: Concomitant use with Sofosbuvir is disadvised due to risks of severe symptomatic bradycardia.
• Tenofovir Disoproxil Fumarate (TDF): Ledipasvir increases TDF exposure, raising the risk of renal toxicity; renal function must be monitored closely if co-administered.

Pregnancy and Breastfeeding

• Sofosbuvir + Ledipasvir Alone: Clinical data on pregnant women are limited. Treatment is generally deferred until after delivery unless immediate therapy is clinically necessary.
• Regimens with Ribavirin: If Ribavirin is added, it causes severe birth defects and embryo-fetal death. Strict double contraception is mandatory for female patients and male partners during treatment and for 6 months after completing therapy.
• Breastfeeding: It is unknown whether Sofosbuvir or Ledipasvir passes into human breast milk. Mothers should consult their treating physician to evaluate benefits versus potential infant risk.

Monitoring During Treatment

Regular clinical evaluations ensure high therapeutic success and safety:

• HBV Screening: Baseline testing for HBsAg and anti-HBc prior to initiating treatment to assess HBV reactivation risk.
• HCV RNA Quantification: Serum HCV RNA tests at baseline and 12 weeks post-treatment to confirm Sustained Virologic Response (SVR12 = cure).
• Renal & Liver Function Tests: Baseline and periodic monitoring of serum creatinine, eGFR, ALT, AST, and total bilirubin.

Generic Sofosbuvir + Ledipasvir

Generic formulations of Sofosbuvir + Ledipasvir are manufactured worldwide under stringent international pharmaceutical standards:

• Cost-Effectiveness: Provides an affordable, highly accessible alternative compared to the brand-name formulation (Harvoni).
• Therapeutic Equivalence: Contains the exact active pharmaceutical ingredients (APIs), delivering bioequivalent viral suppression rates, safety profiles, and cure success.
• Global Access: Expands affordable chronic Hepatitis C management and public health eradication efforts globally.

Frequently Asked Questions (FAQs)

Is Sofosbuvir + Ledipasvir the same as Harvoni?

Yes. Harvoni is the original brand name for the fixed-dose combination of Sofosbuvir (400 mg) and Ledipasvir (90 mg). Generic versions contain the identical active ingredients and work in the exact same way.

Can I take my acid reflux medicine with Sofosbuvir + Ledipasvir?

Yes, but timing is crucial. Ledipasvir needs stomach acid to dissolve properly. Antacids should be taken 4 hours before or after, and PPIs like omeprazole (up to 20 mg) should be taken at the exact same time as your tablet on an empty stomach.

What does "cured" mean in Hepatitis C treatment?

A patient is considered cured when the Hepatitis C virus remains undetectable in the blood 12 weeks after finishing the full medication course (Sustained Virologic Response / SVR12).

Important Safety Information

This article is intended for educational purposes only and does not substitute for expert medical advice. Always consult a qualified hepatologist, gastroenterologist, or infectious disease specialist before initiating, adjusting, or stopping Hepatitis C therapy.

References

• U.S. Food and Drug Administration (FDA) Prescribing Information (Harvoni)
• World Health Organization (WHO) Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Infection
• American Association for the Study of Liver Diseases (AASLD) / Infectious Diseases Society of America (IDSA) HCV Guidance

Contact Us

Are you searching for Generic Sofosbuvir + Ledipasvir, wholesale pricing structures, global availability, or export documentation?

Our expert team is fully equipped to guide you through trusted manufacturer selections, product availability, international licensing, and country-specific import regulations. Contact us today to learn more.

• Sofosbuvir + Ledipasvir